Novartis | NOVN - Pre Tax Profit


Novartis reported $3.84B in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Alcon AG USD 240M 24M Mar/2026
Almirall EUR 30.32M 22M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Autolus Therapeutics Ltd USD -91.52M 12.93M Dec/2025
Bayer EUR -3.37B 2.21B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Fresenius EUR 601M 122M Dec/2025
Fresenius Medical Care EUR 340M 168.46M Mar/2026
Genmab DKK 55M 427M Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
GRIFOLS EUR 190.51M 20.03M Jun/2025
Hikma Pharmaceutical USD 147.5M 3.5M Jun/2025
J&J USD 7.82B 2.86B Mar/2026
Lakefront Biotherapeutics EUR 13.96M 769.2M Mar/2026
Lonza CHF 624M 197M Dec/2024
Merck EUR 401M 886.1M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novartis USD 5.17B 637M Sep/2025
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Orion EUR 113.4M 213.6M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Philips EUR 466M 191M Dec/2025
Recordati EUR 151.97M 7.02M Dec/2025
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
UCB EUR 789M 427M Jun/2025